Connect your AI

Merck & Co. MRK Investing Cash Flow

Investing Cash Flow at other companies

Bristol-Myers SquibbBMY

-$131M+73.7%

PfizerPFE

$785M-76.0%

Johnson & JohnsonJNJ

-$1.04B-250%

Regeneron PharmaceuticalsREGN

-$428.9M-166%

CytokineticsCYTK

$145.49M+37.3%

Phibro Animal HealthPAHC

-$16.81M+7.9%

Other financials

Income statement

Revenue$16.3B+4.9%

Gross profit$12.1B-0.2%

Net income-$4.2B-183%

EPS (diluted)-$1.72-186%

Balance sheet

Cash & equivalents$5.4B-38.2%

Total debt$49.1B+35.8%

Total equity$45.9B-5.1%

Total assets$128.69B+11.8%

Cash flow

Operating cash flow$3.9B+56.7%

CapEx$991.0M-25.4%

Free cash flow$2.9B+150%

Valuation

Market cap$317.37B+60.3%

Enterprise value$361.07B+59.3%

P/E35.5×+23.5×

P/S4.8×+1.7×

Profitability

Gross margin73.9%-2.5pp

Net margin13.6%-13.7pp

FCF margin21.5%-5.2pp

Returns & leverage

Return on equity19%-20.3pp

Debt / equity1.1×+0.3×

Current ratio1.3×-0.1×

Where this comes from

Reported directly by Merck & Co. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Merck & Co.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Merck & Co.'s investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Merck & Co.'s investing cash flow?: Merck & Co. (MRK) reported investing cash flow of -$10.21B in Q1 2026.
How has Merck & Co.'s investing cash flow changed year-over-year?: Merck & Co.'s investing cash flow decreased by 586.6% year-over-year, from -$1.49B to -$10.21B.
What is the long-term trend for Merck & Co.'s investing cash flow?: Over 4 years (2021 to 2025), Merck & Co.'s investing cash flow has grown at a -4.4% compound annual growth rate (CAGR), from -$16.42B to -$13.74B.
What does investing cash flow mean?: Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.